In 2023, coronary artery graft bypass or heart surgery in a private hospital in Malaysia was estimated to cost ****** Malaysian ringgit, the most expensive among other medical procedures. This was followed by stroke treatment, at ****** Malaysian ringgit. Malaysia is one of the most popular destinations for medical tourism in Southeast Asia.

As of April 2024, yellow fever immunization was the most expensive outpatient general treatment for foreign patients at public hospitals in Malaysia. The Malaysian government heavily subsidized the cost of medical treatments at public hospitals.

For 2022, the forecasted gross medical cost trend in the Asia-Pacific region was highest in India, reaching approximately **** percent. This was followed by Malaysia, where the forecasted gross medical cost trend amounted to around **** percent. Comparatively, the forecasted gross medical cost trend in South Korea was estimated to amount to about *** percent in that year.

Malaysia: Healthcare price index, world average = 100: The latest value from 2021 is 43.76 index points, a decline from 51.61 index points in 2017. In comparison, the world average is 67.78 index points, based on data from 165 countries. Historically, the average for Malaysia from 2017 to 2021 is 47.69 index points. The minimum value, 43.76 index points, was reached in 2021 while the maximum of 51.61 index points was recorded in 2017.

Dataset for OPMD and Oral Cancer Healthcare Cost in Public Hospitals in Malaysia

BackgroundEstimation of the economic burden of heart failure (HF) through a complete evaluation is essential for improved treatment planning in the future. This estimation also helps in reimbursement decisions for newer HF treatments. This study aims to estimate the cost of HF treatment in Malaysia from the Ministry of Health’s perspective.Materials and methodsA prevalence-based, bottom-up cost analysis study was conducted in three tertiary hospitals in Malaysia. Chronic HF patients who received treatment between 1 January 2016 and 31 December 2018 were included in the study. The direct cost of HF was estimated from the patients’ healthcare resource utilisation throughout a one-year follow-up period extracted from patients’ medical records. The total costs consisted of outpatient, hospitalisation, medications, laboratory tests and procedure costs, categorised according to ejection fraction (EF) and the New York Heart Association (NYHA) functional classification.ResultsA total of 329 patients were included in the study. The mean ± standard deviation of total cost per HF patient per-year (PPPY) was USD 1,971 ± USD 1,255, of which inpatient cost accounted for 74.7% of the total cost. Medication costs (42.0%) and procedure cost (40.8%) contributed to the largest proportion of outpatient and inpatient costs. HF patients with preserved EF had the highest mean total cost of PPPY, at USD 2,410 ± USD 1,226. The mean cost PPPY of NYHA class II was USD 2,044 ± USD 1,528, the highest among all the functional classes. Patients with underlying coronary artery disease had the highest mean total cost, at USD 2,438 ± USD 1,456, compared to other comorbidities. HF patients receiving angiotensin-receptor neprilysin-inhibitor (ARNi) had significantly higher total cost of HF PPPY in comparison to patients without ARNi consumption (USD 2,439 vs. USD 1,933, p < 0.001). Hospitalisation, percutaneous coronary intervention, coronary angiogram, and comorbidities were the cost predictors of HF.ConclusionInpatient cost was the main driver of healthcare cost for HF. Efficient strategies for preventing HF-related hospitalisation and improving HF management may potentially reduce the healthcare cost for HF treatment in Malaysia.

Malaysia Consumer Price Index (CPI): Health: Medical Products, Appliances & Equipments (MA) data was reported at 117.900 2010=100 in Oct 2018. This records a decrease from the previous number of 118.000 2010=100 for Sep 2018. Malaysia Consumer Price Index (CPI): Health: Medical Products, Appliances & Equipments (MA) data is updated monthly, averaging 108.650 2010=100 from Jan 2010 (Median) to Oct 2018, with 106 observations. The data reached an all-time high of 120.600 2010=100 in May 2018 and a record low of 99.200 2010=100 in Mar 2010. Malaysia Consumer Price Index (CPI): Health: Medical Products, Appliances & Equipments (MA) data remains active status in CEIC and is reported by Department of Statistics. The data is categorized under Global Database’s Malaysia – Table MY.I001: Consumer Price Index: 2010=100.

Bursa Malaysia: PE Ratio: Health Care data was reported at 43.810 Unit in Nov 2018. This records an increase from the previous number of 40.780 Unit for Oct 2018. Bursa Malaysia: PE Ratio: Health Care data is updated monthly, averaging 43.660 Unit from Sep 2018 (Median) to Nov 2018, with 3 observations. The data reached an all-time high of 43.810 Unit in Nov 2018 and a record low of 40.780 Unit in Oct 2018. Bursa Malaysia: PE Ratio: Health Care data remains active status in CEIC and is reported by Bursa Malaysia. The data is categorized under Global Database’s Malaysia – Table MY.Z008: Bursa Malaysia: Price Earnings Ratio.

In 2023, MRI scan was the most expensive type of diagnostic medical service at a private hospital in Malaysia, with an estimated cost of around ***** Malaysian ringgit. By comparison, an x-ray scan cost approximately ** Malaysian ringgit.

In 2023, the consumer price index (CPI) of healthcare in Malaysia was *****, an increase from ***** in the previous year. The CPI is a measure of the weighted average prices of a basket of consumer goods and services, and is used to identify whether a country is undergoing inflation or deflation.

Malaysia Consumer Price Index (CPI): Health: MA: Medical Diagnostic Products data was reported at 110.600 2010=100 in Mar 2025. This records a decrease from the previous number of 110.800 2010=100 for Feb 2025. Malaysia Consumer Price Index (CPI): Health: MA: Medical Diagnostic Products data is updated monthly, averaging 114.600 2010=100 from Jan 2010 (Median) to Mar 2025, with 183 observations. The data reached an all-time high of 120.900 2010=100 in Nov 2021 and a record low of 98.200 2010=100 in Jan 2010. Malaysia Consumer Price Index (CPI): Health: MA: Medical Diagnostic Products data remains active status in CEIC and is reported by Department of Statistics. The data is categorized under Global Database’s Malaysia – Table MY.I001: Consumer Price Index: 2010=100.

Major depressive disorder (MDD) is a growing global health concern, with its economic impact projected to reach USD 6.0 trillion by 2030. Treatment-resistant depression (TRD), characterized by non-responsiveness to initial treatments, adds a significant cost burden. In Malaysia, the National Health and Morbidity Survey 2023 reported a rising prevalence of depression in Malaysia, affecting approximately one million individuals. A combined retrospective chart review and cross-sectional survey was conducted at the Psychiatry and Mental Health Clinic of Hospital Kuala Lumpur (HKL) over an 18-month period, examining 286 patients diagnosed with MDD or TRD. Data were analyzed from governmental and societal perspectives, including direct medical costs, indirect costs, and other resource utilization. TRD patients exhibited significantly higher health-care utilization, including a fivefold increase in the likelihood of attending more than 10 consultations (p = 0.035) and greater use of second-generation antipsychotics (p 

Malaysia Consumer Price Index (CPI): Sabah: Medical Care and Health Expenses data was reported at 112.300 1994=100 in Dec 2000. This stayed constant from the previous number of 112.300 1994=100 for Nov 2000. Malaysia Consumer Price Index (CPI): Sabah: Medical Care and Health Expenses data is updated monthly, averaging 104.650 1994=100 from Jan 1994 (Median) to Dec 2000, with 84 observations. The data reached an all-time high of 112.500 1994=100 in Jun 2000 and a record low of 98.600 1994=100 in Jan 1994. Malaysia Consumer Price Index (CPI): Sabah: Medical Care and Health Expenses data remains active status in CEIC and is reported by Department of Statistics. The data is categorized under Global Database’s Malaysia – Table MY.I020: Consumer Price Index: Sabah: 1994=100.

Malaysia Healthcare BPO Market has experienced substantial growth in recent years, driven by cost-effective healthcare services.

Malaysia Home Healthcare Market growth is driven by cost-effective, patient-centric care, and ongoing innovations in remote care technologies, home healthcare is poised to become a central pillar of modern healthcare delivery systems.

The U.S. Medical Tourism Market size was valued at USD 4.58 USD Billion in 2023 and is projected to reach USD 17.39 USD Billion by 2032, exhibiting a CAGR of 21.0 % during the forecast period. Medical tourism can be considered, when traveling to another country affected by lower medical costs, shorter waiting times for care, or higher quality care service. They can be divided into two main groups elective procedures (e.g. cosmetic surgery, organ transplantation, and fertility treatments) and necessary treatments (as in the case of cardiac surgeries or cancer treatments) according to their importance for a patient's health. Elements cover affordability issues, the availability of the selected procedure types, as well as cultural features. This includes aids that go from cosmetic apps to life-saving procedures. Print Magazines as Competing Sources of News investigated the relationship between print magazines and online media in terms of the dissemination of news. Two main perspectives emerged: that print magazines can compete with online sources as a source of news and that print magazines and online media complement each other as different outlets for news dissemination. In the USA, the increase is the result of the high cost of care, long waiting lists, and quality care offered abroad is the main reason why there is a high number of people who go for it. Especially in countries such as Mexico, Costa Rica and India. Recent developments include: September 2023: Malaysia Healthcare Travel Council (MHTC) announced the successful establishment of a Memorandum of Understanding (MoU) with the U.S.-based Mayo Foundation for Medical Education and Research (MFMER), the largest integrated, not-for-profit medical group practice. Under the MoU, MHTC is engaged with Mayo Clinic Global Consulting to provide strategic advice to advance medical excellence., April 2023: The Mayo Foundation for Medical Education and Research (MFMER) continued its international expansion with the opening of a new patient referral office in developing countries such as India. The office will help patients considering treatment at one of the three Mayo Clinic facilities in the U.S., or at Mayo Clinic Healthcare in London., August 2022: Cedars-Sinai and its affiliate in Qatar, Elegancia Healthcare, a subsidiary of Estithmar Holding Q.P.S.C, announced the opening of The View, a state-of-the-art hospital arising from a shared commitment to excellence in healthcare.. Key drivers for this market are: Rising Access to Pioneering Technologies to Propel Market Growth. Potential restraints include: Rise in Outbound Medical Tourism May Hamper Market Growth Prospects. Notable trends are: High Emphasis to Provide Quality Care for International Patients.

Health access and utilization survey (HAUS) is a cross-sectional, household telephone survey designed by the Public Health Section as a tool to determine refugees’ access to, utilization of, and coverage of key health services across different levels of health facilities as well as to identify critical factors and challenges faced by refugees that may affect health access in a timely manner. UNHCR Malaysia conducted the survey in December 2022 with the help of 23 enumerators and successfully collected data from 718 households comprising of 1,760 individuals. Informed consent was obtained prior to the start of the interview. The average age of the respondents was 34 years (SD = 9 years). Majority of the households were male-headed (87%), married (55%), currently in some form of employment (83%) and originated from Myanmar (74%). Among the head of households, knowledge of available health services were lacking with a third of them (30.8%) unaware of subsidized care at government health facilities for UNHCR document holders while more than half of them were unaware of the availability of hospitalization assistance as provided by IMARET. Nevertheless, most households were able to access health care when needed (93%) although affordability remained a major barrier. The average amount paid by households for primary health services was MYR164 while hospitalization care could cost as much as MYR5,197 on average. In terms of childhood vaccination, 78% children under 5 were able to receive measles or MMR vaccination mainly from government health facilities. However, it is worth noting that the finding did not indicate whether the children had completed the required doses for MMR. Access to reproductive health services remain challenging with slightly more than half of pregnant women faced difficulties accessing antenatal care due to financial barrier. The average cost of delivery care paid by the respondents was MYR3,600. In terms of family planning, only 45.1% received family planning counselling or services post-delivery. Non-communicable diseases were emerging as another health concern affecting as many as 10% of the total households. The top three most common NCD were hypertension, diabetes mellitus and musculo-skeletal diseases. As a result of inclusive national COVID-19 vaccination programme, refugees benefitted from the initiative with 92.6% completing the required doses and 74.6% receiving a booster dose. In summary, findings from this survey indicated the need to strengthen health awareness and information dissemination among refugees while sustainable health financing will help to ease the financial barrier faced by most refugees in need of health services. Advocacy for inclusion in the national health programming in key areas namely communicable and non-communicable diseases, childhood immunization, safe motherhood and family planning will help to promote better health outcomes for refugees.

In 2023, the Malaysian government operating expenditure on healthcare amounted to around ** billion Malaysian ringgit, an increase from the previous year. In 2024, it was forecasted that the healthcare operating expenditure will increase to approximately ** billion Malaysian ringgit.

Malaysia Healthcare Contract Development And Manufacturing Organization Market was valued at USD 2.8 billion in 2024 and is projected to reach USD 6.2 billion by 2032, growing at a CAGR of 10.4% from 2026 to 2032.Malaysia Healthcare Contract Development And Manufacturing Organization Market Drivers and TrendsAccording to Verified Market Research, the following drivers and trends are shaping the market:Regional Manufacturing Hub Strategy - Malaysian government's Economic Transformation Programme positions the country as ASEAN's pharmaceutical manufacturing center, offering tax incentives and streamlined regulatory approval processes that attract international pharmaceutical companies seeking cost-effective production basesCost Arbitrage Advantage - Manufacturing costs in Malaysia are 40-60% lower than developed markets while maintaining international quality standards, making it attractive for pharmaceutical companies seeking to optimize production expenses without compromising regulatory complianceBiosimilar Manufacturing Growth - Increasing demand for affordable biosimilar drugs across ASEAN markets drives investment in biologics manufacturing capabilities, with Malaysia offering skilled workforce and established pharmaceutical infrastructure at competitive ratesExport-Oriented Manufacturing - Strategic location and free trade agreements enable Malaysian CDMOs to serve broader ASEAN and Middle Eastern markets efficiently, with 70% of pharmaceutical production exported to regional marketsDigital Manufacturing Adoption - Implementation of Industry 4.0 technologies in pharmaceutical manufacturing improves operational efficiency and quality control, with government support through Digital Malaysia initiatives accelerating technology adoption

In 2017, approx. X units of medical x-rays were imported into Malaysia; coming up by X% against the previous year. In general, medical x-rays imports continue to indicate a prominent expansion. The most prominent rate of growth was recorded in 2012, when it surged by X% y-o-y. Malaysia imports peaked in 2017, and are likely to see steady growth in the near future.In value terms, medical x-rays imports amounted to $X in 2017.